Erica Palmer
Research Subjects
Erica Palmer has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aniela Jakubowski
Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, MA 02210, USA
1 shared publication - Christopher M. Haqq
Elicio Therapeutics, Boston, USA
1 shared publication - Katherine A. Fitzgerald
Division of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
1 shared publication Lisa K. McNeil
Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, MA 02210, USA
1 shared publication- Lochana M. Seenappa
Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, MA 02210, USA
1 shared publication - Martin P. Steinbuck
Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, MA 02210, USA
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaec1416
Lymph node–targeted DNA engages TBK1/IFN-I–driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs
Adjuvants are immunoactivators capable of shaping the magnitude and quality of antigen-specific immune responses induced by subunit immunization. Presently, there is an acute need for effective adjuvants that safely induce durable and balanced humoral and cellular responses. Here, we engineered a class of Amphiphile (AMP)–modified, immunostimulatory DNA adjuvants designed for targeted delivery to lymph nodes and enhanced stimulation of TANK-binding kinase 1 (TBK1)–mediated danger-sensing pathways to generate strong adaptive immunity and long-term memory with potent recall potential. AMP-DNA adjuvants induced robust interferon type-I (IFN-I)–driven inflammatory environments in mouse and nonhuman primate (NHP) lymph nodes, leading to significantly enhanced cytokine secretion by polyfunctional CD8 + and CD4 + T cells in multiple tissues, as well as strongly elevated T helper cell 1 (T H 1)–associated and neutralizing antibody responses, in the absence of systemic toxicity. These results demonstrate that AMP modification enables lymph node–targeted DNA adjuvants to potently activate IFN-I signaling to generate substantial cellular and humoral responses crucial for vaccine efficacy.
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaec1416
Open AccessLymph node–targeted DNA engages TBK1/IFN-I–driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs
Adjuvants are immunoactivators capable of shaping the magnitude and quality of antigen-specific immune responses induced by subunit immunization. Presently, there is an acute need for effective adjuvants that safely induce durable and balanced humoral and cellular responses. Here, we engineered a class of Amphiphile (AMP)–modified, immunostimulatory DNA adjuvants designed for targeted delivery to lymph nodes and enhanced stimulation of TANK-binding kinase 1 (TBK1)–mediated danger-sensing pathways to generate strong adaptive immunity and long-term memory with potent recall potential. AMP-DNA adjuvants induced robust interferon type-I (IFN-I)–driven inflammatory environments in mouse and nonhuman primate (NHP) lymph nodes, leading to significantly enhanced cytokine secretion by polyfunctional CD8 + and CD4 + T cells in multiple tissues, as well as strongly elevated T helper cell 1 (T H 1)–associated and neutralizing antibody responses, in the absence of systemic toxicity. These results demonstrate that AMP modification enables lymph node–targeted DNA adjuvants to potently activate IFN-I signaling to generate substantial cellular and humoral responses crucial for vaccine efficacy.